BIO in tumult as CEO abruptly exits; Some good PhIII news; Data issues still plague Novartis' gene therapy; Hot targets for M&A?; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
Many thanks to all those who turned up at the EUBIO event in London this week — the whole team is now basking in the positive feedback we got and the photos are giving me FOMO. Endpoints is looking to bring these in-person gatherings to many more corners of the world. Stay tuned.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.